Thank you for visiting the Good Hearts Testing Verification page. If you have used the QR code on the RT-PCR result form we have provided, you will be directed to this page as verification of the authenticity of the RT-PCR test performed.
This Patients RT-PCR test was conducted at our Drive Thru facility located at 4291 NW 36th St, Miami FL 33166 on the date specified on the patient result form. The test was performed by a licensed medical professional under the supervision of the Laboratory and Medical Director, Dr. Mario I. Quiros. The results of the test are specified on the laboratory report provided by the patient.
If you require further verification of a specific traveller's RT-PCR results please contact us at (786) 747-7904 or via email at
This Test was performed using the Visby Medical Covid-19 RT-PCR test. A positive result is considered definitive evidence of infection. However, a negative result does not definitively rule out infection. As with any test, the accuracy relies on many factors: The test may not detect a virus in an infected patient if the virus is not being actively shed at the time or site of sample collection.
The Visby COVID-19 Test is a single-use (disposable), fully integrated, compact device containing a reverse transcription polymerase chain reaction (RT-PCR) based assay for qualitative detection of viral RNA from the SARS-CoV-2. The Visby Medical COVID-19 Test is intended for use by laboratory personnel who have received specific training on the use of the Visby Medical COVID-19 Test. The Visby Medical COVID-19 Test is only for use under the Food and Drug Administration’s Emergency Use Authorization.
This test has not been FDA cleared or approved and this test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARSCoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.